Small study aims to unlock immune chaos in sepsis patients
NCT ID NCT03721809
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 27 adults in intensive care to understand the inflammatory profile of macrophage activation syndrome caused by bacterial sepsis. Researchers measured specific immune markers in blood samples taken over five days. The goal is to gather knowledge that could lead to safer, targeted therapies for this serious condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could point toward safer, targeted treatments for macrophage activation syndrome in sepsis patients.
- What could go wrong
- This is a small, completed observational study with only 27 participants, so findings may not apply broadly or lead directly to new treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACROPHAGE ACTIVATION SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Rouen
Rouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gentler transplant shows promise for kids with blood diseases
- New drug aims to calm dangerous immune storms in Still's and lupus patients
- Can an arthritis drug tame deadly dengue inflammation?
- Researchers launch study to unravel mysteries of rare immune disorder sHLH
- 500 cancer Patients' records reviewed to tame immunotherapy side effects